Stay updated on Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for the anetumab ravtansine and atezolizumab study is displayed, including its terminated status, study design, eligibility criteria, locations, and outcome measures.
    Difference
    61%
    Check dated 2026-11-11T02:20:02.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer now identifies the release as v3.8.0 instead of v3.7.2.
    Difference
    0.2%
    Check dated 2026-11-04T01:08:52.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” The site revision changes from v3.7.1 to v3.7.2; the study record remains unavailable behind a 403 error.
    Difference
    1%
    Check dated 2026-10-21T01:00:17.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The site revision label in the footer changed from v3.7.0 to v3.7.1; the study page remains unavailable with a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T01:07:14.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error, and core study details such as the title, objectives, eligibility criteria, locations, and contacts have been removed, replaced by the error notice.
    Difference
    20%
    Check dated 2026-09-23T00:59:19.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0, replacing the previous v3.6.6, indicating a platform update that does not change the trial details shown.
    Difference
    0.1%
    Check dated 2026-09-16T00:13:53.000Z thumbnail image

Stay in the know with updates to Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Anetumab Ravtansine Plus Atezolizumab in NSCLC Clinical Trial page.